Lutetium-177 (Lu-177) Market Growth Analysis, Market Dynamics, Key Players and Innovations, Outlook and Forecast 2024-2030

Market Value and Growth Projection:

  • The global Lutetium-177 (Lu-177) market witnessed a valuation of US$ 740 million in 2023.

  • Anticipated to experience significant growth, projecting a market value of US$ 6.5 billion by 2030.

  • Demonstrates an impressive Compound Annual Growth Rate (CAGR) of 22.96% during the forecast period from 2023 to 2030.

Lutetium-177 (Lu-177) is a medical isotope used in targeted radionuclide therapy for treating certain types of cancer, such as neuroendocrine tumors and prostate cancer. It's an innovative therapy that delivers targeted radiation directly to cancer cells, minimizing damage to healthy tissues. Lu-177 can be attached to targeting molecules, which seek out and bind to specific cancer cells, enabling precise treatment. This precision makes it an effective option for cancer patients whose disease is advanced or has spread. It's an exciting advancement in the field of cancer treatment, offering new hope for those who may have few other treatment options.

Regional Analysis:

  1. North America:

    • Market Expansion and Projection:

      • Estimated growth from $420.03 million in 2022 to reach $2.52 billion by 2029.

      • Indicates a substantial CAGR of 19.93% during the forecast period from 2023 to 2029.

  2. Europe:

    • Market Dynamics and Growth Forecast:

      • Estimated increase from $167.12 million in 2022 to reach $1.32 billion by 2029.

      • Demonstrates a remarkable CAGR of 24.08% during the forecast period from 2023 to 2029.

Major Global Manufacturers:

  • Key Players in the Lutetium-177 (Lu-177) Market:

    • Dominated by major manufacturers such as NRG, NTP Radioisotopes, ANSTO, Bruce Power, Eckert & Ziegler Strahlen, Advanced Accelerator Applications, and SHINE Technologies, among others.

    • In 2022, the top three vendors collectively accounted for an impressive 89.65% of the total revenue, highlighting a concentrated market.

  • Market Share Insights:

    • The dominance of the top three vendors underscores a concentrated market, emphasizing the significant influence and market presence of these key players.

    • Understanding the market concentration is crucial for stakeholders to assess competitive dynamics and potential collaborations or strategic partnerships.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Lutetium-177 (Lu-177), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lutetium-177 (Lu-177).

The Lutetium-177 (Lu-177) market size, estimations, and forecasts are provided in terms of output/shipments (Doses) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Lutetium-177 (Lu-177) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Lutetium-177 (Lu-177) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, production, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

By Company

  • NRG

  • NTP Radioisotopes

  • ANSTO

  • Bruce Power

  • Eckert & Ziegler Strahlen

  • Polatom

  • Advanced Accelerator Applications

  • SHINE Technologies

  • SCK CEN

Segment by Type

  • Non-carrier-added

  • Carrier-added

Segment by Application

  • Nuclear Therapy

  • Others

Production by Region

  • North America

  • Europe

Consumption by Region

  • North America

  • U.S.

  • Canada

  • Asia-Pacific

  • China

  • Japan

  • South Korea

  • Southeast Asia

  • India

  • Rest of Asia-Pacific

  • Europe

  • Germany

  • France

  • U.K.

  • Italy

  • Russia

  • Rest of Europe

  • Latin America

  • Mexico

  • Brazil

  • Rest of Latin America

  1. Rising use in targeted radionuclide therapy: Lu-177 is seeing high growth for precision cancer treatments like Lu-177-PSMA-617 for metastatic castration-resistant prostate cancer.

  2. Advances in global supply infrastructure: Investments into expanding Lu-177 production capacity via key reactors likeAustralia's OPAL, Netherlands' Petten are addressing supply deficits.

  3. Increasing R&D into new radioconjugates: Pharma players are actively evaluating Antibody, peptide, small-molecule carriers paired to Lu-177 for therapies in other oncology areas.

  4. Progress with generator separation technologies: Efforts to optimize separations from Ytterbium-176 parent isotope for reliable large-scale Lu-177 production.

  5. Emergence of theranostic applications: Leveraging Lu-177 in tandem with diagnostic radionuclides like Ga-68 offers targeted personalized therapy based on imaging.

  6. Commercial model evolution: Traditionally supply from government nuclear reactors is shifting towards private, market-based models partnering with radiopharmas to ensure outputs.